Demonstration of safety in Alzheimer's patients for intervention with an anti‐hypertensive drug Nilvadipine: results from a 6‐week open label study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Nilvadipine may lower rates of conversion from mild‐cognitive impairment to Alzheimer's disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the further exaggeration of a drop in BP. Objective: The aim of this study was to investigate the safety and tolerability of nilvadipine in AD patients. Methods: AD patients in the intervention group (n = 56) received nilvadipine 8 mg daily over 6‐weeks, compared to the control group (n = 30) who received no intervention. Differences in systolic (SBP) and diastolic (DBP) blood pressure, before and after intervention, was assessed using automated sphygmomanometer readings and ambulatory BP monitors (ABP), and change in OH using a finometer. Reporting of adverse events was monitored throughout the study. Results: There was a significant reduction in the SBP of treated patients compared to non‐treated patients but no significant change in DBP. Individuals with higher initial blood pressure (BP) had greater reduction in BP but individuals with normal BP did not experience much change in their BP. While OH was present in 84% of the patients, there was no further drop in BP recorded on active stand studies. There were no significant differences in adverse event reporting between groups. Conclusion: Nilvadipine was well tolerated by patients with AD. This study supports further investigation of its efficacy as a potential treatment for AD. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 2×
“a prospective randomized clinical trial, showed a decline in the incidence of dementia (mostly AD) with nitrendipine intervention in hypertensive individuals (Forette et al., 1998; Forette et al., 2002).”
BackgroundForette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 2×
“a prospective randomized clinical trial, showed a decline in the incidence of dementia (mostly AD) with nitrendipine intervention in hypertensive individuals (Forette et al., 1998; Forette et al., 2002).”
BackgroundMathias, C. J., Mallipeddi, R., & Bleasdale-Barr, K. (1999) · Journal of Neurology · doi:10.1007/s004150050479 · Cited by 178 · cited 2×
“, 1994) and the symptoms associated with OH include dizziness, light-headedness, falls, visual disturbances and loss or near-loss of consciousness (Craig, 1994; Mathias et al., 1999).”
BackgroundCalcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging
Yasar, S., Corrada, M., Brookmeyer, R., & Kawas, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.009 · Cited by 116
Clinical presentation of orthostatic hypotension in the elderly
Craig, G. M. (1994) · Postgraduate Medical Journal · doi:10.1136/pgmj.70.827.638 · Cited by 51
Compliance and Antihypertensive Efficacy of Amlodipine Compared With Nifedipine Slow-Release
Mounier-Vehier, C. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00485-8 · Cited by 37 · cited 1×
“This has previously been described with controlled release calcium channel antagonists (Dupont et al., 1991; Mounier-Vehier et al., 1998).”
Background
Cited by
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 309
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193
Self-citationCalcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Paris, D., Ait-Ghezala, G., Bachmeier, C., Laco, G., Beaulieu-Abdelahad, D., Lin, Y., Jin, C., Crawford, F., & Mullan, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608091 · Cited by 73
“In addition, a short treatment duration with nilvadipine in AD patients has been shown to reduce cognitive decline (21, 22).”
BackgroundResultSelf-citationβ-Secretase: its biology as a therapeutic target in diseases
Wang, H., Li, R., & Shen, Y. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.008 · Cited by 69
Romero-Ortuno, R., O’Connell, M. D., Finucane, C., Soraghan, C., Fan, C. W., & Kenny, R. A. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-73 · Cited by 54
“For example, in a previous study, the peripheral CCB Nilvadipine did not aggravate OH in a sample of patients with Alzheimer’s disease, despite significant reduction in the SBP of treated patients [49].”
ResultSelf-citation
Metadata
- Authors
- Kennelly, S. P., Abdullah, L., Paris, D., Parish, J., Mathura, V., Mullan, M., Crawford, F., Lawlor, B. A., & Kenny, R. A.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2010-10-29
- Volume
- 26
- Issue
- 10
- Pages
- 1038-1045
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2040905269
- Cited by
- 37
- References
- 6
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.